{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"33"}]}],"title":"Testosterone at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"276","value":"186"}]}],"title":"Testosterone at 4 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"251","value":"171"}]}],"title":"Testosterone at 12 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"By serum ultrasensitive total testosterone test (Quest Diagnostics)","dispersionType":"Standard Deviation","groups":[{"description":"Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment","id":"OG000","title":"Testosterone Cream"}],"paramType":"MEAN","populationDescription":"Per protocol, participants assigned to the Testosterone arm who completed 12 weeks of assigned treatment and had testosterone measurement at baseline, 4 weeks and 12 weeks.","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Total Testosterone Levels","type":"SECONDARY","unitOfMeasure":"ng/dl"}